MeSH term
Frequency | Condition_Probility | Adolescent | 51 | 0.0 |
Child | 25 | 0.0 |
Diet Surveys | 2 | 8.0 |
Edetic Acid/*therapeutic use | 3 | 75.0 |
Female | 120 | 0.0 |
Ferric Compounds/*therapeutic use | 3 | 75.0 |
Ferritin/blood | 35 | 22.0 |
*Food, Fortified | 3 | 23.0 |
Hemoglobins/drug effects | 3 | 20.0 |
Humans | 203 | 0.0 |
Iron/blood | 8 | 8.0 |
Male | 98 | 0.0 |
Time Factors | 11 | 0.0 |
Liver/metabolism | 3 | 0.0 |
Middle Aged | 75 | 0.0 |
Research Support, Non-U.S. Gov't | 111 | 0.0 |
Adult | 99 | 0.0 |
Blood Donors | 2 | 0.0 |
Comparative Study | 25 | 0.0 |
Erythrocytes/*metabolism | 3 | 1.0 |
Italy | 4 | 0.0 |
Prospective Studies | 8 | 0.0 |
Reference Values | 8 | 0.0 |
Sensitivity and Specificity | 9 | 0.0 |
Statistics, Nonparametric | 4 | 0.0 |
Aged | 42 | 0.0 |
Aged, 80 and over | 13 | 0.0 |
Antithrombin III | 2 | 3.0 |
Biological Markers/blood | 9 | 0.0 |
Case-Control Studies | 3 | 0.0 |
Fibrin/metabolism | 3 | 4.0 |
Peptide Fragments/blood | 2 | 1.0 |
Peptide Hydrolases/blood | 2 | 4.0 |
Predictive Value of Tests | 4 | 0.0 |
Prothrombin | 2 | 4.0 |
Severity of Illness Index | 2 | 0.0 |
Tumor Markers, Biological/blood | 3 | 1.0 |
Animals | 21 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
Immunoblotting | 2 | 0.0 |
Mice | 9 | 0.0 |
Amino Acid Sequence | 5 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 2 | 0.0 |
Molecular Sequence Data | 6 | 0.0 |
Phosphorylation | 4 | 0.0 |
Protein Binding | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
Fibrin/*analysis | 7 | 58.0 |
Fibrin Fibrinogen Degradation Products/*analysis | 4 | 8.0 |
Reference Standards | 2 | 0.0 |
Reproducibility of Results | 4 | 0.0 |
Solubility | 8 | 0.0 |
C-Reactive Protein/analysis | 2 | 0.0 |
Synovial Fluid/*immunology | 2 | 3.0 |
Drugs, Chinese Herbal/*therapeutic use | 2 | 2.0 |
English Abstract | 25 | 0.0 |
Dietary Supplements | 5 | 6.0 |
Ferritin/*blood | 28 | 42.0 |
Hemoglobins/analysis | 17 | 5.0 |
Nutritional Status | 10 | 7.0 |
Protoporphyrins/blood | 6 | 28.0 |
Receptors, Transferrin/*blood | 2 | 14.0 |
Fibrin Fibrinogen Degradation Products/metabolism | 2 | 2.0 |
*Fibrinolysis | 2 | 1.0 |
Plasminogen Activator Inhibitor 1/blood | 3 | 2.0 |
Biological Availability | 2 | 0.0 |
Diet | 7 | 1.0 |
Diet Records | 3 | 12.0 |
Hemoglobins/*analysis | 6 | 11.0 |
Intestinal Absorption | 2 | 1.0 |
Iron, Dietary/*administration & dosage/pharmacokinetics | 2 | 100.0 |
Longitudinal Studies | 2 | 0.0 |
Nutritional Requirements | 5 | 16.0 |
Infant, Newborn | 7 | 0.0 |
Kinetics | 16 | 0.0 |
Mass Fragmentography | 2 | 0.0 |
Plasminogen/*metabolism | 2 | 5.0 |
Tumor Cells, Cultured | 7 | 0.0 |
Cohort Studies | 2 | 0.0 |
Ferritin/*blood/*drug effects | 2 | 100.0 |
Iron/*blood | 9 | 22.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 12 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 27 | 0.0 |
Risk Factors | 7 | 0.0 |
Algorithms | 2 | 0.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Statistics | 2 | 0.0 |
Temperature | 2 | 0.0 |
Antithrombin III/analysis | 3 | 1.0 |
Fibrin/analysis | 5 | 16.0 |
Fibrin Fibrinogen Degradation Products/analysis | 3 | 2.0 |
Follow-Up Studies | 5 | 0.0 |
Peptide Fragments/analysis | 4 | 1.0 |
Peptide Hydrolases/analysis | 3 | 2.0 |
Prothrombin/analysis | 4 | 5.0 |
Random Allocation | 2 | 0.0 |
Treatment Outcome | 5 | 0.0 |
Cross-Sectional Studies | 12 | 0.0 |
Hemoglobins/metabolism | 10 | 6.0 |
*Nutritional Status | 4 | 5.0 |
Rural Health | 2 | 11.0 |
Vegetables | 2 | 8.0 |
Women's Health | 2 | 5.0 |
Erythrocytes/metabolism | 2 | 1.0 |
Genotype | 3 | 0.0 |
Apolipoproteins B/blood | 3 | 1.0 |
Fatty Acids, Nonesterified/blood | 3 | 1.0 |
Insulin/blood | 2 | 0.0 |
Liver/*metabolism | 3 | 0.0 |
Triglycerides/blood | 8 | 0.0 |
Anemia, Iron-Deficiency/*epidemiology/prevention & control | 2 | 100.0 |
India/epidemiology | 2 | 2.0 |
Pregnancy | 11 | 0.0 |
Pregnancy Complications, Hematologic/*epidemiology | 2 | 50.0 |
Pregnancy Trimesters | 2 | 14.0 |
Prevalence | 13 | 0.0 |
Iron/*metabolism | 13 | 10.0 |
Cholesterol/blood | 7 | 0.0 |
In Vitro | 2 | 0.0 |
Lipids/*metabolism | 2 | 0.0 |
Lipoproteins, LDL Cholesterol/blood | 3 | 0.0 |
Particle Size | 3 | 1.0 |
Anemia, Iron-Deficiency/*epidemiology | 4 | 100.0 |
Blood Coagulation Tests | 2 | 1.0 |
Cells, Cultured | 13 | 0.0 |
Age Factors | 2 | 0.0 |
Homozygote | 3 | 0.0 |
Iron/metabolism | 3 | 2.0 |
Mass Screening | 4 | 2.0 |
Phenotype | 2 | 0.0 |
Gestational Age | 3 | 0.0 |
Adolescent Nutrition | 2 | 66.0 |
Anemia, Iron-Deficiency/blood/*epidemiology | 5 | 100.0 |
Anthropometry | 3 | 1.0 |
Child Nutrition | 2 | 50.0 |
Iron/blood/*deficiency | 3 | 60.0 |
Nutrition Assessment | 4 | 16.0 |
Socioeconomic Factors | 4 | 2.0 |
Transferrin/analysis | 8 | 9.0 |
Vitamin A/blood | 2 | 8.0 |
Embryonic and Fetal Development/*physiology | 2 | 4.0 |
Flow Cytometry | 2 | 0.0 |
Immunohistochemistry | 3 | 0.0 |
Anemia, Iron-Deficiency/*prevention & control | 3 | 100.0 |
Body Mass Index | 2 | 0.0 |
Double-Blind Method | 3 | 0.0 |
Analysis of Variance | 4 | 0.0 |
Exercise/*physiology | 2 | 0.0 |
Antithrombins/analysis | 2 | 12.0 |
Biological Markers/*blood | 2 | 1.0 |
*Hemostasis | 2 | 1.0 |
Hemoglobinometry | 2 | 6.0 |
ADP-ribosyl Cyclase | 3 | 0.0 |
*Antigens, CD | 2 | 0.0 |
Antigens, CD34/analysis | 2 | 0.0 |
Antigens, Differentiation/analysis | 2 | 0.0 |
Cell Division | 4 | 0.0 |
Membrane Proteins/*genetics | 3 | 0.0 |
Cattle | 3 | 0.0 |
Rats | 4 | 0.0 |
Interleukin-3/pharmacology | 5 | 1.0 |
Recombinant Proteins/pharmacology | 7 | 0.0 |
Signal Transduction/drug effects/*physiology | 2 | 0.0 |
Stem Cell Factor/pharmacology | 5 | 3.0 |
Cell Division/drug effects | 5 | 0.0 |
Clone Cells | 2 | 0.0 |
Colony-Forming Units Assay | 3 | 0.0 |
Diagnosis, Differential | 2 | 0.0 |
Prognosis | 4 | 0.0 |
Thrombosis/*diagnosis | 2 | 66.0 |
Child, Preschool | 15 | 0.0 |
Erythrocyte Indices | 6 | 9.0 |
Iron, Dietary/*administration & dosage | 5 | 83.0 |
Regression Analysis | 3 | 0.0 |
*Diet | 3 | 1.0 |
Energy Intake | 2 | 1.0 |
Meat | 2 | 6.0 |
Hematocrit | 4 | 1.0 |
Pregnancy Complications, Hematologic/*prevention & control | 2 | 50.0 |
Gene Expression | 2 | 0.0 |
Substrate Specificity | 2 | 0.0 |
*Alleles | 2 | 0.0 |
Apolipoproteins E/*genetics | 2 | 0.0 |
Lipoproteins, LDL/*blood | 4 | 2.0 |
Lipoproteins, VLDL/blood | 3 | 1.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Fetal Blood/*cytology | 3 | 1.0 |
Interleukin-3/*pharmacology | 2 | 1.0 |
Stem Cell Factor/*pharmacology | 3 | 5.0 |
Incidence | 2 | 0.0 |
Infant | 15 | 0.0 |
Hematopoiesis/*physiology | 2 | 2.0 |
Ligands | 2 | 0.0 |
*Neoplasm Proteins | 2 | 0.0 |
*Receptors, Cytokine | 2 | 1.0 |
Platelet Count | 2 | 0.0 |
Receptors, Transferrin/blood | 2 | 10.0 |
Anemia, Hypochromic/diagnosis | 3 | 75.0 |
Injections, Intravenous | 2 | 0.0 |
Iron/*deficiency | 6 | 37.0 |
Renal Dialysis/*adverse effects | 4 | 2.0 |
Prothrombin/*metabolism | 2 | 6.0 |
Retrospective Studies | 2 | 0.0 |
Antithrombin III/metabolism | 2 | 1.0 |
Blood Coagulation/*physiology | 2 | 1.0 |
Tyrosine/metabolism | 2 | 0.0 |
Apolipoproteins B/*blood | 3 | 1.0 |
Deuterium | 2 | 7.0 |
Infusions, Intravenous | 3 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 2 | 0.0 |
Lipoproteins, VLDL/*blood | 4 | 5.0 |
Models, Biological | 5 | 0.0 |
Fibrin/*metabolism | 4 | 10.0 |
Proto-Oncogene Protein c-met | 2 | 1.0 |
Anemia/*drug therapy/etiology | 2 | 6.0 |
*Renal Dialysis | 4 | 0.0 |
*Erythrocyte Indices | 2 | 15.0 |
Heterozygote | 3 | 0.0 |
Lipids/blood | 3 | 0.0 |
Lipoproteins/blood | 3 | 0.0 |
*Mutation | 2 | 0.0 |
Pedigree | 2 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Cell Lineage | 2 | 0.0 |
Lipoproteins, VLDL/metabolism | 6 | 5.0 |
Bone Marrow/drug effects | 2 | 2.0 |
Bone Marrow Cells | 3 | 0.0 |
Cell Line | 8 | 0.0 |
Erythropoietin/pharmacology | 2 | 1.0 |
Interleukin-6/pharmacology | 2 | 0.0 |
Transfection | 5 | 0.0 |
ROC Curve | 3 | 1.0 |
Apolipoproteins B/metabolism | 2 | 2.0 |
Chylomicrons/*metabolism | 2 | 6.0 |
Lipoproteins, VLDL/*metabolism | 2 | 2.0 |
Anemia, Hypochromic/epidemiology | 2 | 100.0 |
Sweden/epidemiology | 3 | 2.0 |
Transferrin/*metabolism | 2 | 3.0 |
Lipoprotein Lipase/metabolism | 2 | 1.0 |
Lipoproteins, HDL/blood | 3 | 1.0 |
Transferrin/metabolism | 5 | 3.0 |
Lipoproteins/*blood | 3 | 0.0 |
Lipoproteins, LDL/blood | 2 | 0.0 |
Fibroblasts/metabolism | 3 | 0.0 |
Gene Expression/drug effects | 3 | 0.0 |
Antigens, CD/analysis | 2 | 0.0 |
Antigens, CD34 | 2 | 0.0 |
Stem Cell Factor | 6 | 6.0 |
Acute Disease | 2 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 2 | 1.0 |
Hematopoietic Cell Growth Factors/*pharmacology | 3 | 6.0 |
Thymidine/metabolism | 2 | 0.0 |
Partial Thromboplastin Time | 2 | 1.0 |
Prothrombin Time | 2 | 1.0 |
Erythropoietin/*therapeutic use | 3 | 3.0 |
Recombinant Proteins/therapeutic use | 3 | 0.0 |
Apolipoproteins E/metabolism | 2 | 3.0 |
Lipoprotein Lipase/blood | 3 | 3.0 |
Vitamin A/analogs & derivatives/blood | 2 | 33.0 |
Kidney Failure, Chronic/therapy | 2 | 5.0 |
Erythropoiesis | 3 | 3.0 |
Radioimmunoassay | 2 | 0.0 |
Iron/therapeutic use | 2 | 20.0 |
Lymphocyte Activation | 3 | 0.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Simvastatin | 2 | 6.0 |
Antibodies, Monoclonal | 2 | 0.0 |
*Blood Coagulation | 2 | 0.0 |
Apolipoproteins B/*metabolism | 6 | 6.0 |
Lipoproteins/*metabolism | 3 | 1.0 |
Lipoproteins, LDL/metabolism | 4 | 1.0 |
Combined Modality Therapy | 2 | 0.0 |
Renal Dialysis | 2 | 0.0 |
Erythrocyte Volume | 3 | 15.0 |
Tumor Markers, Biological/*blood | 2 | 0.0 |
Phosphotyrosine | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Hemochromatosis/blood/*genetics | 2 | 22.0 |
Histocompatibility Antigens Class I/*genetics | 2 | 0.0 |
*Mutation, Missense | 2 | 0.0 |
Base Sequence | 2 | 0.0 |
Administration, Oral | 2 | 0.0 |
Blood Transfusion/adverse effects | 2 | 5.0 |
Ferritin/analysis | 2 | 11.0 |
Gene Frequency | 2 | 0.0 |
Bone Marrow/metabolism | 2 | 1.0 |
Lipoproteins, VLDL/*blood/isolation & purification | 2 | 40.0 |
Nigeria | 2 | 3.0 |
Alcohol Drinking | 2 | 1.0 |
Questionnaires | 2 | 0.0 |
Sex Factors | 2 | 0.0 |
Hemochromatosis/etiology/*genetics | 2 | 50.0 |
Iron/*blood/*deficiency | 2 | 100.0 |
Alleles | 2 | 0.0 |
Risk | 2 | 0.0 |
Iron/*administration & dosage | 2 | 40.0 |
Blood Transfusion | 2 | 1.0 |
Molecular Weight | 3 | 0.0 |
*Blood Transfusion | 2 | 1.0 |
*Lymphocyte Activation | 2 | 0.0 |
Thymus Hormones/*pharmacology | 2 | 18.0 |
